Navigation Links
Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012
Date:10/24/2011

SUNNYVALE, Calif., Oct. 24, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its first quarter of fiscal year 2012, ended September 30, 2011 on Tuesday, November 8, 2011 after the market closes.

A conference call to review the results of its first quarter of fiscal year 2012 will begin at 2:00 p.m. PST/5:00 p.m. EST and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Derek Bertocci, senior vice president and chief financial officer.

The conference call dial-in numbers are 1-800-789-2884 (USA) or +1-617-614-6207 (International), Conference ID: 13731949. In addition, a dial-up replay of the conference call will be available beginning November 8, 2011 at 5:00 p.m. PST/8:00 p.m. EST and ending on November 22, 2011. The replay telephone number is 1-888-286-8010 (USA) or +1-617-801-6888 (International), Conference ID:  47941705.

A live webcast of the call will also be available from the Investor Relations section of the corporate website at http://www.accuray.com/investors.  A webcast replay can be accessed on the corporate website beginning Tuesday, November 8, 2011 at approximately 5:00 p.m. PST/8:00 p.m. EST.  The replay will remain available until Accuray announces its results for the second quarter of fiscal 2012, ending December 31, 2011.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies &#
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
2. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
3. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
4. Accuray Announces Regionalized Management Strategy for Americas
5. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
6. Accuray Introduces the CyberKnife(R) VSI(TM) System
7. Accuray Announces Results for Second Quarter Fiscal 2010
8. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
9. Accuray Hires General Manager for Japan
10. Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference
11. Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Trovagene, Inc. (NASDAQ:  TROV), a developer of ... for the three months ended March 31, 2015. ... presented favorable clinical results at ASCO GI, AACR, ... Precision Cancer Monitoring platform,s ability to detect and ... cancers," said Antonius Schuh, Ph.D., chief executive officer ...
(Date:5/5/2015)... NEW YORK , May 5, 2015  IBM ... it is collaborating with more than a dozen leading ... identify and personalize treatment options for their patients. The ... cognitive capabilities to reduce from weeks to minutes the ... profile and gather relevant information from medical literature to ...
(Date:5/5/2015)... , May 5, 2015 ... at $94.9 million in 2014, and is estimated to ... of 7.8% from 2014 to 2019. Browse ... Device Market for an analysis of industry trends and ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... NEW YORK, Sept. 6, 2011 ... market research report is available ... Licensing Strategies of Large ... Pipelines and the Patent Cliff ...
... Global regenerative medicine company, Mesoblast Limited, (ASX: ... from the European Medicines Agency (EMA) to begin ... Europe for its lead cardiovascular product Revascor(TM) in ... heart failure after a major heart attack. Revascor(TM) ...
Cached Medicine Technology:Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 2Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 3Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 4Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 5Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 6Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 7Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 8Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 9Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 10Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 11Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 12Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 13Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 14Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 15Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 16Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 2Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 3Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 4
(Date:5/5/2015)... 2015 ProTexting, LLC – a ... deploy Mobile Engagement Campaigns and other Mobile solutions, introduces ... can now leverage the power of Mobile Marketing to ... subscribers’ e-mail addresses into the Constant Contact Platform. , ... the growing trend of multi-channel marketing would become more ...
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Hope Initiative, a new study aimed at determining how ... patients. RG is an international non-profit providing rare disease ... sequencing technology, connections to scientists and researchers, and help ... crowdfunding. , “I am excited to see how crowdfunding ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 On April ... Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... LA’s leading producer of sustainable product placement in TV ... the world’s top providers of ecologically sound and socially ... premier red carpet event that makes appearances at various ...
(Date:5/5/2015)... Brookfield, Wis. (PRWEB) May 05, 2015 ... security solutions created the Sensatec® ST750 Fall Management Solution ... recording advising the monitored patient or resident to wait ... up. Caregivers also have the choice of 16 different ... into a nurse call system such as Code Alert®. ...
(Date:5/5/2015)... In the upbeat Moms Helping Moms video, real ... support each other. Parenting is a tough job, but ... so much easier. Mothers talk about how relating and ... and help them realize there’s no perfect parent; everyone is ... clearly dear friends share that it's just that, the friendship ...
Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2
... ... within football’s international arena, it is with great pleasure that international direct selling identity, ... of Asian football. , ... (PRWEB) February 19, 2010 -- As the Official Direct Selling Supporter of the ...
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... ... ... ... ...
... ... , ... , , , , ... ...
... ... ... ... ...
... Francisco has signed a partnership agreement with Genentech, Inc., ... discover and develop drug candidates for neurodegenerative diseases. ... research acumen in neuroscience and will collaborate with UCSF ... work of several researchers at the UCSF Small Molecule ...
Cached Medicine News:Health News:QuestNet and AFC: Raising the Bar of Asian Football 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 3Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 2Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 3Health News:Centene Corporation to Webcast Medical Management Systems Update 2Health News:Centene Corporation to Webcast Medical Management Systems Update 3Health News:Centene Corporation to Webcast Medical Management Systems Update 4Health News:UCSF enters drug discovery agreement with Genentech 2Health News:UCSF enters drug discovery agreement with Genentech 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: